Skip to content
Screener

Exagen Inc. XGN Q3 2025 earnings

Reported November 4, 2025 · Before market open

Revenue$17.2MBeat by $708.3K
EPS-$0.19Miss by $0.06
Revenue estimate$16.5M
EPS estimate-$0.13

Next report

Nov 3, 2026 (In 3 weeks)
Revenue estimate$18.3M
EPS estimate-$0.19

Financials

Q3 2025

Income statement

See full
Revenue$17.2M+37.9%
Gross profit$10.1M+44.3%
Operating income-$3.1M+33.5%
Net income-$7.1M-41.0%
EPS (diluted)-$0.31-10.7%

Balance sheet

See full
Cash & equivalents$35.9M+61.2%
Total debt$27.8M+18.0%
Total equity$18.1M+41.0%
Total assets$62.8M+44.1%

Cash flow

See full
CapEx$275.0K+87.1%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$241.82M+331%
Enterprise value$233.76M+307%
P/S3.8×+2.8×

Profitability

See full
Gross margin59.9%+1.1pp
Operating margin-19.6%-4.4pp
Net margin-29.9%-0.4pp

Returns & leverage

See full
Return on equity-122.8%+107pp
Debt / equity1.5×-0.3×
Current ratio4.1×0.0×

Segments

By segment

See full
Reportable Segment$17.2M+37.9%

FAQ

When did Exagen Inc. report Q3 2025 earnings?
Exagen Inc. (XGN) reported Q3 2025 earnings on November 4, 2025 before market open.
What were Exagen Inc.'s Q3 2025 revenue and EPS?
Exagen Inc. reported revenue of $17.2M and eps of $-0.19 for Q3 2025.
Did Exagen Inc. beat estimates in Q3 2025?
Revenue beat the consensus estimate of $16.5M by $708.3K. EPS missed the consensus estimate of $-0.13 by $0.06.
How did Exagen Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 37.9% from $12.5M a year earlier and eps grew 32.1% from $-0.28.
Where can I find Exagen Inc.'s Q3 2025 SEC filings?
You can read the 8-K earnings release (0001274737-25-000069) and the 10-Q periodic report (0001274737-25-000071) directly on SEC EDGAR. The filing index links above go to sec.gov.